Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

US12180227B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Martina Delbeck · Essen, DE
• Michael Hahn · Langenfeld, DE
• Thomas Müller · Bonn, DE
• Klemens Lustig · Wuppertal, DE
• Karl COLLINS · Düsseldorf, DE
• Niels Lindner · Wuppertal, DE
• Janine Nicolai · Essen, DE
• Moritz Beck-Broichsitter · Darmstadt, DE
• Udo Albus · Florstadt, DE
• Doris Gehring · Kelkheim, DE
• Björn Rosenstein · Salmünster, DE

Key dates

• Filing date: Jul 16, 2021
• Grant date: Dec 31, 2024
• Expiry date: Jan 18, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.